A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Juan M SaavedraEnrique Sanchez-Lemus

Abstract

Long-term pretreatment with an angiotensin II AT1 antagonist blocks angiotensin II effects in brain and peripheral organs and abolishes the sympathoadrenal and hypothalamic-pituitary-adrenal responses to isolation stress. We determined whether AT1 receptors were also important for the stress response of higher regulatory centers. We studied angiotensin II and corticotropin-releasing factor (CRF) receptors and benzodiazepine binding sites in brains of Wistar Hannover rats. Animals were pretreated for 13 days with vehicle or a central and peripheral AT1 antagonist (candesartan, 0.5 mg/kg/day) via osmotic minipumps followed by 24 h of isolation in metabolic cages, or kept grouped throughout the study (grouped controls). In another study, we determined the influence of a similar treatment with candesartan on performance in an elevated plus-maze. AT1 receptor blockade prevented the isolation-induced increase in brain AT1 receptors and decrease in AT2 binding in the locus coeruleus. AT1 receptor antagonism also prevented the increase in tyrosine hydroxylase mRNA in the locus coeruleus. Pretreatment with the AT1 receptor antagonist completely prevented the decrease in cortical CRF1 receptor and benzodiazepine binding produced by isola...Continue Reading

References

Dec 1, 1978·Pharmacology, Biochemistry, and Behavior·A S LippaB Beer
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·B GrimaJ Mallet
Apr 1, 1993·Pharmacology, Biochemistry, and Behavior·S M AndersonE B De Souza
Jan 1, 1995·Brain Research Bulletin·A IsraelJ M Saavedra
Jan 1, 1996·Biological Signals·G YangY Zhu
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·D W SchulzJ Heym
Aug 1, 1997·General Pharmacology·A Fernández-LópezP Calvo Fernández
Dec 31, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R J PrimusD W Gallager
Jan 27, 1998·Pharmacology, Biochemistry, and Behavior·R J Rodgers, N J Johnson
Mar 21, 1998·Pharmacology & Therapeutics·F Zavala
Nov 24, 1999·Biological Psychiatry·G F Koob
Dec 10, 1999·Regulatory Peptides·J M Saavedra
Nov 7, 2000·The Journal of Comparative Neurology·K Van PettP E Sawchenko
Sep 15, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M J MillanA Dekeyne

❮ Previous
Next ❯

Citations

May 2, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Wolfgang H Sommer, Juan M Saavedra
Aug 15, 2012·Psychopharmacology·Jan Józef BraszkoPiotr Jakubów
Mar 5, 2009·Cellular and Molecular Neurobiology·Julius BenickyJuan M Saavedra
Dec 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Julius BenickyJuan M Saavedra
Aug 14, 2009·Clinical and Experimental Pharmacology & Physiology·A S MecawiL C Reis
Oct 22, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eric G KrauseRandall R Sakai
Jan 25, 2014·Frontiers in Neuroendocrinology·Eric P ZorrillaGeorge F Koob
Jul 9, 2014·BioMed Research International·Maria de los Angeles MarinzaldaGustavo Baiardi
Oct 4, 2013·BioMed Research International·Maria Constanza PazClaudia Bregonzio
Oct 30, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·K V Anil KumarKilari Eswar Kumar
Dec 17, 2014·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Anjana BaliAmteshwar Singh Jaggi
May 18, 2016·PloS One·Nofar TorikaSigal Fleisher-Berkovich
Feb 13, 2019·International Journal of Molecular Sciences·Shaip Krasniqi, Armond Daci
Sep 8, 2009·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Sylwia FudalejFrederic C Blow
Jan 6, 2009·Annals of the New York Academy of Sciences·Jaroslav PavelJuan M Saavedra
Mar 16, 2019·Annals of the New York Academy of Sciences·Gillian A Matthews, Kay M Tye
May 22, 2007·Stress : the International Journal on the Biology of Stress·Juan M Saavedra, Julius Benicky
Jun 25, 2008·Stress : the International Journal on the Biology of Stress·Agnieszka Cudnoch-JedrzejewskaAgnieszka Wsół
Jul 23, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Augusto Martins LimaMarco Antônio Peliky Fontes
Aug 2, 2017·BMC Medicine·João VianBrisa S Fernandes
Jun 7, 2014·Pharmacological Reports : PR·Dominik Wincewicz, Jan J Braszko
Jan 19, 2016·CNS Neuroscience & Therapeutics·Michael OgierLaurent Bezin
Dec 15, 2010·Clinical and Experimental Pharmacology & Physiology·Dmitry N Mayorov
Aug 8, 2018·Pharmacological Reports : PR·Roman Tashev, Margarita Ivanova
Sep 22, 2020·Pharmacology & Therapeutics·Jason D Vadhan, Robert C Speth
Sep 1, 2018·Pharmacological Reports : PR·Roman Tashev, Margarita Ivanova
Apr 18, 2021·Cellular and Molecular Neurobiology·Taíz F S BrasilFernando M A Corrêa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.